A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer.

In HER2+ MBC, continuing trastuzumab (T) after the progression during a first-line T-based regimen, represents 1 of the possible strategies, even if few data from randomized trials exist in this setting.